Share This Alert with Traders You Know! BOLD STOCKS BREAK-OUT ALERT:

Trade Alert ALZM: Allezoe Medical Holdings, Inc. (OTCBB: ALZM) – Substantial Discount to Recent Highs May be Strong Buying Opportunity Dear Members, I know that anyone that is as much in to smallcap stocks as I am is closely monitoring Allezoe (OTCBB: ALZM). Over that past month ALZM has traded over 80 million shares, with prices as high as $2.60 a share. With Wednesday`s close of just $1.88, there could be a very significant buying opportunity. That price is a 27% discount off recnet highs achieved just six trading days prior.

Let`s first look at the fundamenals of ALZM:

Allezoe Medical Holdings, Inc. (OTCBB: ALZM) is the sole shareholder of Organ Transport Systems, Inc. which is focused on the development and commercialization of its LifeCradle(R) organ preservation technology.

Organ Transport has been in existence for nearly 12 years, has had more than $10 million invested in it over the years in the research and development for LifeCradle(R) technology.

Pre-clinical Experiments “Significantly Extend Useful Life of Hearts” In the pre-clinical experiments, researchers have concluded that the LifeCradle(R) significantly extends the useful life of hearts and provides a healthier heart after similar time periods of preservation compared to the current standard of care of heart preservation i.e. static, cold storage in “a picnic cooler” on ice.

Raising Funds for Final FDA Clinical Trials ALZM reported that on March 31, 2011, it received an initial investment to continue preparing its Life Cradle(R) technology for clinical trials.

According to Michael Holder, Chairman and CEO of Allezoe, “This initial investment will allow us to further our clinical trial preparations and provides bridge financing while we are negotiating a larger capital infusion from institutional investors to support the trials.” The Company is now working to raise additional capital from private sources to fund the final FDA clinical trials to bring the LifeCradle(R) to market.

LifeCradle(R) Tested LifeCradle(R) has been tested in more than 225 animal heart preservation experiments as well as over 15 discarded human heart experiments, leading to peer reviewed and published articles in the Journal of Transplantation and the Journal of Heart and Lung Transplantation as well as presentations by the OTS research collaborators at national and international meetings like the International Society for Heart and Lung Transplantation Conferences and the American Association of Thoracic Surgery.

More to come on ALZM… We will be watching this one very closely.

Forward Looking Statement: This is not an offer to sell any Allezoe (“ALZM”) related securities. Offers for any given security are made only through applicable offering circulars and related documents filed with the SEC pursuant to the Securities Act of 1933 or the Securities Exchange Act of 1934. Certain statements contained herein and subsequent oral statements made by and on behalf of ALZM may contain “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.

Such forward looking statements are identified by words such as “intends”, “anticipates”, “believes”, “expects”, and “hopes” and includes, without limitation, statements regarding ALZM`s plan of business operations, product research and development activities, anticipated revenues and expenses and potential contractual arrangements and obligations. Also, our management may make forward-looking statements orally to investors, analysts, the media and others. Forward-looking statements express our expectations or predictions of future events or results. They are not guarantees and are subject to many risks and uncertainties. There are a number of factors beyond our control that could cause actual events or results to be significantly different from those described in the forward-looking statements. Any or all of our forward-looking statements in this report or in any other public statements we make may turn out to be wrong. We undertake no obligation to publicly update or review any forward-looking statements, whether as a result of new information, future developments or otherwise.

AHRO Disclosure: Pentony Enterprises LLC has been retained as a consultant by a non-controlling third party. To avoid all potential conflicts of interest, we never sell shares into the open market during an active market awareness or investor relations program. This means that as we release new information about a particular client company either on our site or otherwise authored by us, you can be confident we are not selling shares at the same time. We hold no shares and will not be receiving further compensation in shares or that is share related during this period. Our total compensation is ten thousand dollars. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

Most Recent News for ALZM Allezoe (ALZM): OTS and Research Collaborators to Attend and Present at International Society for Heart and Lung Transplantation (ISHLT) FRISCO, TEXAS, Apr 04, 2011 (MARKETWIRE via COMTEX) — Allezoe (OTCBB:

ALZM) announces that members of the Organ Transport Systems (“OTS”) leadership team will attend the annual meeting of the International Society for Heart and Lung Transplantation (ISHLT) April 13-16, 2011 in San Diego, California, where OTS collaborators will be presenting results from their latest preclinical studies. OTS plans to redefine human organ transplantation with its LifeCradle(R) device through better preservation and ease of use of the LifeCradle(R) in the current donor organ procurement process, at minimal costs. The preclinical research performed by the OTS collaborators further substantiates these plans.

The International Society for Heart and Lung Transplantation (ISHLT) meeting and scientific sessions are held annually to gather the most prominent thoracic surgeons, physicians, research scientist, engineers, and others involved in heart and lung transplantation to share their most recent findings for best practices and to review any new, emerging technologies with their peers from around the world.

This year, the cardiothoracic research team from University of Texas Southwestern Medical Center in Dallas, led by Dr. Michael E. Jessen, Professor & Chairman of the Dept. of Cardiothoracic Surgery, will be presenting, `Retrograde Coronary Sinus Perfusion: An alternate approach for machine perfusion preservation of donor hearts for transplantation` authored by ML Cobert, LM West, ME Jessen, and M Peltz. Dr. Peltz will be presenting the paper at the ISHLT conference in San Diego. The study, which utilized an OTS LifeCradle(R) prototype, showed that the two preferred routes for perfusing the heart tissue in a transplant procedure both provided adequate oxygen and nutrients to maintain metabolism. Controlling the temperature so the hearts do not get too cold, as is the case when they are preserved on ice (the current standard method), and maintaining metabolism, prevents tissue damage during the preservation period and potentially gives the transplant team a more viable organ for the recipient.

Over the past several years OTS research collaborators have presented their pre-clinical research findings using the LifeCradle(R) HR donor heart preservation device at the ISHLT meetings showing that donor hearts can be better preserved by providing oxygen and nutrients to the heart tissue rather than just storing them on ice until they can be transplanted. This could potentially extend the preservation period and provide more time for delivery to recipients at greater distances. Currently, almost 10% of viable donated hearts are discarded because of time/geographical constraints, i.e. the donor hearts cannot be procured, transported, and then transplanted in the short 3-4 hours desirable for best outcomes.

During the ISHLT conference, Dr. Thomas D. Franklin, Jr., PhD, EVP of Research & Regulatory Affairs at OTS, will be meeting with members of OTS`s Medical Advisory Board and its Clinical Trial Steering Committee that have been reviewing and guiding the OTS research and clinical plans over the past several years. The meetings will allow OTS`s advisors to review the proposed clinical trial protocols and discuss ongoing research projects.

OTS announced last week that it had received initial funding to continue preparations for clinical trials of its LifeCradle(R) device.

For more details please visit the OTS website at www.organtransportsystems.com or the ISHLT website at www.ishlt.org.

About Allezoe (ALZM) Allezoe Medical Holdings, Inc. (ALZM) is the holding company for Organ Transport Systems, Inc. (“OTS”) and for future acquisitions targeted to medical products, solutions and services. We believe it is possible to create value for shareholders as well as recipients of healthcare services at the same time, and we do so by seeking out the highest quality medical devices. OTS, headquartered in Frisco, Texas, is a biomedical company engaged in developing, patenting, and commercializing portable hypothermic, oxygenated preservation and transport technology for human organs. OTS plans to redefine human organ transplantation through better preservation with its LifeCradle(R) product line.

FORWARD LOOKING STATEMENT This announcement is not an offer to sell any Allezoe (“ALZM”) related securities. Offers for any given security are made only through applicable offering circulars and related documents filed with the SEC pursuant to the Securities Act of 1933 or the Securities Exchange Act of 1934. Certain statements contained herein and subsequent oral statements made by and on behalf of ALZM may contain “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements are identified by words such as “intends”, “anticipates”, “believes”, “expects”, and “hopes” and includes, without limitation, statements regarding ALZM`s plan of business operations, product research and development activities, anticipated revenues and expenses and potential contractual arrangements and obligations. Also, our management may make forward-looking statements orally to investors, analysts, the media and others. Forward-looking statements express our expectations or predictions of future events or results. They are not guarantees and are subject to many risks and uncertainties. There are a number of factors beyond our control that could cause actual events or results to be significantly different from those described in the forward-looking statements. Any or all of our forward-looking statements in this report or in any other public statements we make may turn out to be wrong. We undertake no obligation to publicly update or review any forward-looking statements, whether as a result of new information, future developments or otherwise.

Contacts:

Allezoe Medical Holdings, Inc.

Media Department 214-290-8031 media@allezoe.com www.allezoe.com ..

Get BOLD STOCKS on TWITTER:

http://www.sgurunews.com/emailmarketer/link.phpM596&N10&L8&F=T Get The BOLD STOCKS RSS FEED:

http://www.sgurunews.com/emailmarketer/link.phpM596&N10&L1&F=T BALZM Disclosure: Pentony Enterprises LLC has been retained as a consultant by a non-controlling third party. To avoid all potential conflicts of interest, we never sell shares into the open market during an active market awareness or investor relations program. This means that as we release new information about a particular client company either on our site or otherwise authored by us, you can be confident we are not selling shares at the same time. We hold no shares and will not be receiving further compensation in shares or that is share related during this period.

Our total compensation is ten thousand dollars. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk – Pentony Enterprises LLC is BoldStocks.com- 1601 Berwick Drive | McKinney, Texas 75070 | 469-252-3030.

AHRO · ALZM · BALZM · ISHLT

Your email client cannot read this email.

To view it online, please go here:

http://www.sgurunews.com/emailmarketer/display.phpM596&C=c7c822f09eefcb0dac0453b7afd60b76&S02&L=3&N28 Why You Must Get In On The Next Mega Trend Now! It Could Make You 5 Times Richer By Summer…

Your First Rapid 510% On Genmed (GENM) Could Be In Your Hands In 100 Days Or Less… Then, You Could Make As Much As 989% Before Snow Flies! Andy Carpenter Carpenter Global Stock Advisory ACTION ALERT Genmed SYMBOL GENM Dear Micro-Cap Investor:

Today`s media machine doesn`t let investment sweet spots like this last for long. Outstanding opportunities, like the one you`re about to see, are ripe today… and devoured by hungry investors tomorrow.

And this one is sweet. It is the one you`ve been waiting for.

You could pocket your first 510% success in less than 100 days…

then watch as that could double by Christmas… a 10 bagger The Death Of Communism Has Created A Vast, Unprecedented Opportunity For Big-Picture Investors Who Know The Power Of Free Markets All you have to do is get out ahead of the newest MEGA TREND that`s developing in Europe`s drug sector. It is a big deal… one that gets bigger every day.

This is a fast-expanding market that was cracked wide open when much of Europe cast off the shackles of communism and embraced the American form of Capitalism.

And, one company I`ve discovered looks poised to claim a highly profitable corner of this quarter-trillion-dollar market.

The company is Genmed (GENM). It sells products in the booming generic-drugs market.

My Top Picks Tend To Explode…

Rapidly Jumping 289%… 576%… 669% Hello, my name is Andrew Carpenter, editor of the Carpenter Global Stock Advisory. Some people call me the maverick genius of the micro-cap market.

I am known for finding soon-to-be-hot companies just before they pop…this talent for finding hidden gems has led major global newspapers, such as The Wall Street Journal, USA Today and The Shanghai Security News to write huge profiles about me.

In fact, The Wall Street Journal said that I have an uncanny knack for discovering companies… that fly below the radar screens of most Wall Street analysts, and that I Dig up information on companies Wall Street can`t be bothered with. USA Today said that I… Predicted one stock winner after another.

So people pay attention when I announce a new discovery.

Many of them will read a new Special Report I have written about Genmed (GENM), which your can read for FREE today just below here.

Genmed (GENM) It Could Be Your Best Global Opportunity Of The Year You can access it for FREE as part of an introduction to my newsletter… but you`re under no obligation… I won`t even ask for you email address. FREE is free to me.

You see, I`ve been looking for a company in the super-hot European drug sector… in particular, not some old, tired dinosaur… rather, I sought a young company… one with start-up power… and the potential to deliver explosive gains.

GENMED fills that bill.

Genmed`s Supplier Has Increased Production 300% To Keep Up With GENM`s Demand The Special Report covers all Genmed`s tremendous upside…

its rip-roaring potential to dominate the generic drug sector.

In my Genmed Special Report you see…

-How the big players of old are suddenly at a disadvantage to young Genmed (GENM)…

-Why one of Genmed`s suppliers had to increase production by 300% just to keep up with orders…

-Why Holland and the Czech Republic could hold the key to your fortunes…

-Why a new agreement in England opens a 1,200-pharmacy, 500-hospital market…

-How this final wave of European privatization could multiply your money by nearly 10X by Christmas.

There Is A Massive Demand For Less Expensive Drugs…

Genmed Looks Set To Shoot At Least 510% By July 4, Because It`s Selling FDA Approved Generic Drugs In A Huge, Newly Deregulated Market So, let`s get you to the Special Report now… take moment of your time to discover what could be one of the most important companies in the newly booming European drug sector…

a company you could own today for pennies! And, thanks for your time today.

( http://www.sgurunews.com/emailmarketer/link.phpM596&N02&L07&F=T) Andrew Carpenter, Editor, The Carpenter Global Stock Advisory P.S. Please don`t lose sight of the fact that as generic drug sales are set to boom in Europe after years of being held in check, Genmed is lined up and ready to supply Europe with top selling generic drugs.

And, you can be there to capture all the potential what could be as much as 510% by this summer… and the possibility to see it double after that.

You`ll find it all here for FREE.

( http://www.sgurunews.com/emailmarketer/link.phpM596&N02&L07&F=T) IMPORTANT NOTICE AND DISCLAIMER: Andrew Carpenter`s (Endorser) track record was compiled from calculations derived from documentation of his Carpenter Global Stock Advisory (CGSA) newsletter. Said newsletter and documentation were made available to CGSA subscribers. No representation is made that actual purchases and sales were made at the prices stated.

Facts stated in this article were supplied to endorser from third-party sources. Endorser makes no representations as to such facts` reliability, accuracy or completeness. Endorser is not responsible for errors or omissions.

Endorser does not claim any special expertise or knowledge regarding the European generic or pharmaceutical drug sector or of its OTC drug sector. Endorser is neither acting as an investment advisor nor providing individual investment advice. Andrew Carpenter and The Carpenter Global Stock Advisory OWN NO SHARES, OPTIONS, WARRANTS in Genmed Holding Corp. (GENM), Also, GENM neither approved nor paid for this specific advertisement. Readers should perform their own due diligence. The information presented is provided for information purposes only and the endorsement is not to be used or considered as an offer or the solicitation of an offer to sell or to buy or subscribe for securities.

Endorser has not taken any steps to ensure that the securities referred to in this report are suitable for any particular investor. Any securities referenced by Endorser may not be suitable for you and it is recommended that you consult an independent investment advisor if you are in doubt about such investments. Nothing in the endorsement constitutes investment, legal, accounting or tax advice or a representation that any investment or strategy is suitable or appropriate to your individual circumstances or otherwise constitutes a personal recommendation to you. Information, opinions and estimates referenced in the endorsement reflect a judgment at its original date of publication and are subject to change without notice.

The price and value of the securities mentioned in the endorsement can fall as well as rise, and may have a high level of volatility. High volatility securities may experience sudden and large falls in their value, leading to losses. High volatility investments may also be difficult to sell. Similarly, it may prove difficult for you to obtain reliable information about the value or risks to which such an investment is exposed. The endorsement may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the report refers to website material of Endorser, Endorser has not reviewed any recommended or linked site and takes no responsibility for the content contained therein. Such address or hyperlink is provided solely for your convenience and information and the content of the linked site does not in any way form part of the endorsement. Accessing such websites or following any link shall be at your own risk. Further, you are advised to read and carefully consider the additional explanations of risk factors in Genmed Holding Corp`s SEC filings that can be found online in the SEC`s EDGAR database at www.SEC.gov. Neither Andrew Carpenter nor his publication is offering securities for sale. Carpenter has been contracted to receive five thousand dollars by a third party, Wellington Manner LLC, for coverage of Genmed Holding Corp. In addition, the Carpenter Global Stock Advisory expects to receive new subscriber revenue as a result of this advertising effort. Finally, Penny Stocks are EXTREMELY RISKY.

You should consult with your registered investment adviser before investing to determine suitability and risk tolerance. Andrew Carpenter and The Carpenter Global Stock Advisory assume no risk for investor losses or profits. The information contained herein contains forward-looking information within the meaning of section 27a of the Securities Act of 1993, as amended, and section 21e of the Securities Exchange Act of 1934, as amended, including statements regarding expected growth of the featured company. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act, statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may affect the Genmed Holding`s actual results of operations. Factors that could cause actual results to differ include size and growth of the market, the Company`s ability to fund its capital requirements in the near term and in the long term; pricing pressures, technology issues etc.

There is no guarantee that past results are indicative of future performance.

Compensation and Other Disclosures The content of this message is published by Genmed Holding Corp and sent to select email lists through Lake Group Media, Inc. (“Lake”) to provide readers with information on selected publicly traded companies. Factual information is obtained from public filings and other sources deemed to be reliable; however, neither Genmed Holding Corp nor Lake takes responsibility for verifying the accuracy of such information and they make no representation that such information is accurate or complete. Certain of the statements in this Update may be considered forwarded looking statements. Genmed Holding Corp and Lake make no representation and provide no assurance or guaranty that such forward looking statements will prove to be accurate. See the companies filings with the Securities and Exchange Commission for factors that may cause results to be significantly different. Statements of opinion and belief are those of the authors and/or editors of this Update, and are based solely upon the information possessed by such authors and/or editors; no inference should be drawn that such authors or editors have any special or greater knowledge about the company or companies profiled or any particular expertise in the industries or markets in which the profiled company or companies compete. The reader should verify all claims and complete his own due diligence before investing in any securities of the profiled company or companies.

Neither Genmed Holding Corp, Lake, nor anyone involved in the publication or dissemination of this Update is a registered investment adviser or broker/dealer. Genmed Holding Corp and Lake make no recommendation that the purchase of securities of the company or companies profiled in this Update are suitable or advisable for any person or that an investment in such securities will be profitable. In general, given the nature of the company or companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree! of risk. An investor in such securities should be prepared and able t o bear a loss of his or her entire investment. Nothing in this Update should be construed as an offer or solicitation to buy or sell any securities of any profiled company. Lake has been retained to provide direct marketing services for the company profiled in this Update and receives compensation for those services.

Further, Lake and its employees and affiliates may own, or may purchase and sell, securities of the company or companies profiled. Lake undertakes no obligation to inform readers about the ownership or trading activities of it or its employees or affiliates in the securities of the profiled company or companies. Lake has the following compensation arrangements with the company or companies profiled in this Update: Lake receives an advertising fee ranging from $1,000 to $100,000 for each direct marketing list recommended and ordered for the dissemination of this Update.

Paid Advertising – Pentony Enterprises LLC “PE” The report and content of this presentation is a paid advertisement. It was paid for by a non-controlling third party for dissemination of this copy. We have taken no shares. To avoid all potential conflicts of interest, we never sell shares into the open market during an active market awareness or investor relations program. This means that as we release new information about a particular client company either on our site or otherwise authored by us, you can be confident we are not selling shares at the same time. We hold no shares and will not be receiving further compensation in shares or that is share related during this period. Total compensation from the third party for sending this and other advertising copy associated with GENM totals no more than three thousand three hundred dollars. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. As advertising, PE was hired for the distribution of the attached content. PE did not author or endorse the content, and as a rule never does when hired for advertising. Paid Advertising – Pentony Enterprises LLC 1601 Berwick Drive McKinney, Texas 75070 (469) 252-3031.

To stop receiving these emails:http://www.sgurunews.com/emailmarketer/

CGSA · GENM · RISKY

Your email client cannot read this email.

To view it online, please go here:

http://www.sgurunews.com/emailmarketer/display.phpM596&C=c7c822f09eefcb0dac0453b7afd60b76&S17&L=3&N42 “This One Trade Could Have You Cashing Out A 5,192% Winner By June 1st, 2011!” By pulling the trigger on the company that some are already calling the “Apple of Emerging Markets” today, you could watch as – a meager $5,000 investment soars to $264,600 or $10,000 explode into $529,200 – as KNKT`s Smartphones and tablets take surging economies like China, India and Brazil By Storm! Greetings Friend, What you`re about to hear is both shocking and amazing Because never before has their been one, single company that could offer you a very real chance to profit big as lucrative foreign markets recreate themselves from struggling 3rd World countries into economic powerhouses.

After decades of struggling, some of the last century`s poorest nations have rebuilt their economies the ground up, and are taking their place along side the world`s elite economic power – The United States of America.

And while China, India and Brazil may be leading the charge of this “new money movement”, they`re not alone, as many other countries are joining their assault on the world economy. The unprecedented growth of these countries is truly a wonder But even more, this growth is offering opportunities for people like us to profit along side the Wall Street Billionaires unlike any other time in history.

You see, this economic growth is creating a huge demand for the products of the western world And while cars, computers and cable television is on their list of “must haves”, nothing tops the demand for the wireless electronics that have become commonplace among Western society.

Smartphones and tablet`s may be “old hat” to us, but for the citizens of these flourishing nations, they are the “Holy Grail” of elite status.

But where as these products from top producers like Apple, RIM and HTC are priced far outside of the price range for many, there is one company that is giving these people what they want And that company is Kunekt.

You see, Kunekt is offering this “new world middle-class” comparable Smartphones and tablets for half of the price of their closest competitor – Apple.

By doing so, this forward thinking company is giving us more than an all-but-guaranteed chance to garner 5,192% gains They`re also offering us a way to secure a foothold across the entire spectrum of emerging markets – instead of just being able to invest in just one or two of these proven money makers – Kunekt is allowing us to pillage them all! Let me show you how KNKT could turn you into an emerging markets Millionaire. Get the whole story by selecting the link below you`ll be glad you did! Eric Dickson Editor, Breakaway Stocks PS. Remember, not only is Kunekt (KNKT) offering you a very real chance at 5,192% profits, but they`re also giving us a way to invest across the entire emerging markets spectrum. It`s why some experts are predicting Apple-sized profits in the very near future for early investors. Read on Disclosure: Pentony Enterprises LLC is being compensated thirty six hundred dollars by a non-controlling third party. To avoid all potential conflicts of interest, we never sell shares into the open market during an active market awareness or investor relations program. This means that as we release new information about a particular client company either on our site or otherwise authored by us, you can be confident we are not selling shares at the same time. We hold no shares and will not be receiving further compensation in shares or that is share related during this period.

Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

Pentony Enterprises LLC 1601 Berwick Drive McKinney, Texas 75070 (469) 252-3031.

To stop receiving these emails:http://www.sgurunews.com/emailmarketer/

KNKT

Share This Alert with Traders You Know! InfoSpi, Inc. (OTCQB: ISPI) Bold Alert on ISPI: InfoSpi, Inc. (OTCQB: ISPI) Patent Value $17.2 Million According to Pellegrino Report Dear Members, As you look over ISPI, I want you to look at the PELLEGRINO REPORT.

Understand, InfoSpi, Inc. (OTCQB: ISPI) operates within the energy saving lighting industry through its wholly owned subsidiary NexPhase Lighting, Inc.

The Wow-Power InfoSpi delivers is the value of its initial patent: $17.2 million as valued by Pellegrino and Associates.

The Company has announced that it will continue to reveal details of the value of this patent. This could be a serious value driver in ISPI. It could be a good idea to be ready to move prior to the release of additional information as promised by ISPI in their recent press release. The details ISPI has released to date on the Patent follow.

NexPhase Intellectual Property Valued $17.2M The preliminary information from an independent appraisal report commissioned prior to its acquisition of NexPhase Lighting, Inc., on the value of the new, patent pending NexPhase intellectual property has been obtained.

In total, the report estimates that the value of the initial patent filed by NexPhase at $17.2 million. It has been noted that this value applies to only a few key market applications of the NexPhase patent, leaving aside other market applications to pursue.

Pellegrino and Associates is a world-class firm that specializes in early stage, intellectual property, as well as software valuations for clients large and small around the world.

This patent in particular is anticipated to be the springboard of NexPhase`s growth. The Company will continue to release summary information on the report`s findings and projections about this patent along with perceptions regarding the report`s interpretation regarding the Company`s planning process and revenue generation potential.

Volume is very likely to pick up as we go into an intense week next week.

Keep a close eye here.

Thank you, John Pentony ISPI`s Most Recent Releases:

MORE BREAKING NEWS THIS MORNING FROM ISPI:

InfoSpi, Inc. Subsidiary, NexPhase Lighting, Inc., Releases Additional Information Concerning Its Agreement With Cree, Inc.

MIAMI, FL, Mar 03, 2011 (MARKETWIRE via COMTEX) — NexPhase Lighting, Inc., (“NexPhase”), a designer, developer and manufacturer of high efficiency, high quality LED intelligent lighting fixtures and a wholly-owned subsidiary of InfoSpi, Inc. (OTCQB: ISPI) (PINKSHEETS: ISPI) (the “Company”), today released additional background information about Cree, Inc., with which it has signed an Ingredient Branding and Trademark License Agreement.

Jon Cooper, President of NexPhase, stated, “Cree is a publicly traded company, currently trading on the NASDAQ exchange. Cree is currently trading above $51 per share with a current market cap of $5.61B. Cree is leading the LED lighting revolution and making energy-wasting traditional lighting technologies obsolete through the use of energy-efficient, environmentally friendly LEDs.

“Cree worked closely with NexPhase in the development of our intelligent 2`X2` Troffer with NexSense technology. Cree has been intrigued with the progress NexPhase has made in such a short period of time. Scott White from Cree recently stated that, `NexPhase has tremendous potential in the commercial LED lighting space.` From a philosophical standpoint, if NexPhase wins, Cree wins.” “NexPhase chose Cree as our primary LED provider over several other competing LED companies,” said Ty Ramsey, NexPhase`s COO. “Cree made it easy for us. They`re leading the world with innovative, world-class LEDs, combined with extremely attractive pricing. What really set them apart from the competition was the professionalism of their engineering and sales support teams.” NexPhase placed their first order for Cree product in early February, with the anticipation of ramping up to full production volumes in Q3.

About NexPhase Lighting, Inc.

NexPhase Lighting, Inc. is a designer and developer of proprietary high quality LED (light-emitting diode) lighting fixtures and control systems for commercial applications. It believes its products will be the lowest cost, highest efficacy fixtures available in the LED Lighting Industry. All NexPhase lighting products incorporate its proprietary “NexSense TechnologyTM,” which provides benefits well beyond the generally acknowledged advantages of all other LED lighting fixtures. NexSense control systems use a unique, “patent pending” wireless protocol, which provides for an unsurpassed reduction in architecture and infrastructure installation cost in commercial applications, as well as significantly reduced maintenance and ongoing operation costs.

For more information about NexPhase Lighting, Inc. visit:

http://www.sgurunews.com/emailmarketer/link.phpM596&N99&L44&F=T About InfoSpi, Inc.

InfoSpi, Inc. was founded to develop innovative, practical and cost-effective solutions to some of the most significant environmental challenges facing industries and governments around the world.

Additionally, these solutions must show promise of generating profits for the company. Specifically the company has determined that one industry that meets both of the above mentioned prongs of criteria is the Energy Saving Lighting Industry.

For additional information about InfoSpi visit: www.InfoSpiinc.com.

Safe Harbor Statement:

This release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. Certain statements set forth in this press release constitute “forward-looking statements.” Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words “estimate,” “project,” “intend,” “forecast,” “anticipate,” “plan,” “planning,” “expect,” “believe,” “will likely,” “should,” “could,” “would,” “may” or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company`s actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company`s ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company`s limited operating history, the limited financial resources, domestic or global economic conditions — activities of competitors and the presence of new or additional competition and conditions of equity markets.InfoSpi, Inc. Subsidiary, NexPhase Lighting, Inc., Signs Ingredient Branding and Trademark License Agreement With Cree, Inc.

MIAMI, FL, Mar 02, 2011 (MARKETWIRE via COMTEX) — InfoSpi, Inc. (OTCQB:

ISPI) (PINKSHEETS: ISPI), (the “Company”), today announced that its wholly-owned subsidiary, NexPhase Lighting, Inc., (“NexPhase”), a designer, developer and manufacturer of high efficiency, high quality LED intelligent lighting fixtures, has signed an Ingredient Branding and Trademark License Agreement with Cree, Inc.

Cree, Inc. ( www.cree.com), headquartered in Durham, North Carolina, is a market-leading innovator of lighting-class LEDs. Cree will be providing their MX-6 LEDs for use in the NexPhase troffer. The MX-6 provides better color consistency and higher reliability than incumbent solutions. The MX-6 delivers higher lumen output without having to compromise between light output and efficacy. For more information about the MX-6 you can find Cree`s data sheet for this product here. Going forward, this branding agreement allows NexPhase to display the Cree logo on its website, marketing materials and packaging.

About NexPhase Lighting, Inc.

NexPhase Lighting, Inc. is a designer and developer of proprietary high quality LED (light-emitting diode) lighting fixtures and control systems for commercial applications. It believes its products will be the lowest cost, highest efficacy fixtures available in the LED Lighting Industry. All NexPhase lighting products incorporate its proprietary “NexSense Technology (TM),” which provides benefits well beyond the generally acknowledged advantages of all other LED lighting fixtures. NexSense control systems use a unique, “patent pending” wireless protocol, which provides for an unsurpassed reduction in architecture and infrastructure installation cost in commercial applications, as well as significantly reduced maintenance and ongoing operation costs.

For more information about NexPhase Lighting, Inc. visit:

http://www.sgurunews.com/emailmarketer/link.phpM596&N99&L44&F=T About InfoSpi, Inc.

InfoSpi, Inc. was founded to develop innovative, practical and cost-effective solutions to some of the most significant environmental challenges facing industries and governments around the world.

Additionally, these solutions must show promise of generating profits for the company. Specifically the company has determined that one industry that meets both of the above mentioned prongs of criteria is the Energy Saving Lighting Industry.

For additional information about InfoSpi visit: www.InfoSpiinc.com.

Safe Harbor Statement:

This release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. Certain statements set forth in this press release constitute “forward-looking statements.” Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words “estimate,” “project,” “intend,” “forecast,” “anticipate,” “plan,” “planning,” “expect,” “believe,” “will likely,” “should,” “could,” “would,” “may” or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company`s actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company`s ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company`s limited operating history, the limited financial resources, domestic or global economic conditions — activities of competitors and the presence of new or additional competition and conditions of equity markets.

InfoSpi, Inc.

19495 Biscayne Blvd., Suite 411 Aventura, Florida 33180 Phone (305) 932-9795 Fax (305)932-9033Contact InfoSpi, Inc.

InfoSpi, Inc.

19495 Biscayne Blvd., Suite 411 Aventura, Florida 33180 Phone (305) 932-9795 Fax (305)932-9033 Get BOLD STOCKS on TWITTER:

http://www.sgurunews.com/emailmarketer/link.phpM596&N99&L8&F=T Get The BOLD STOCKS RSS FEED:

http://www.sgurunews.com/emailmarketer/link.phpM596&N99&L1&F=T unsubscribe.

Bold Stocks (Bold) provides its members with the latest news, press releases, and research reports for all the companies highlighted on our web site, www.BoldStocks.com. Bold utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by Bold to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. Bold encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and Bold makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Bold is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed onhttp://www.sgurunews.com/emailmarketer/link.phpM596&N99&L6&F=T or mentioned herein. This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Forward-looking statements describe future expectations, plans, results, or strategies and are generally preceded by words such as may, future, plan or planned, will or should, expected, anticipates, draft, eventually or projected. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies= annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.

You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and Bold undertakes no obligation to update such statements. ISPI Disclosure: Pentony Enterprises LLC entered into an investor relations consulting and market awareness contract in February 2011. We were hired through INS, a third party on behalf of ISPI for six thousand dollars. We have taken no free trading shares. To avoid all potential conflicts of interest, we never sell shares into the open market during an active market awareness or investor relations program. Pentony Enterprises is not a registered investment adviser or a broker/dealer.

Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

ISPI · OTCQB

Your email client cannot read this email.

To view it online, please go here:

http://www.sgurunews.com/emailmarketer/display.phpM596&C=c7c822f09eefcb0dac0453b7afd60b76&S48&L=3&N68 This is a third party paid advertisement sent to you featuring the opinions of John Person.

The author, John Person, is completely independent of, and not affiliated with Pentony Enterprises LLC or its affiliates.

..

Ocean of oil could make you FIVE TIMES RICHER in just 18 Months-COUGF Another Brand New Video Report Just Released http://www.sgurunews.com/emailmarketer/link.phpM596&N48&L88&F=T Fellow Investor, Profit-seeking investors not reading this will miss out.

But you won`t.

Two Words…Alberta Oil.

Cougar Oil and Gas (COUGF) could deliver a 516% profit, turning $5,000 into $25,821.

Even more exciting — that 516% jump could be just the beginning.

The reason is easy to see.

Select Here For Free Video Report http://www.sgurunews.com/emailmarketer/link.phpM596&N48&L88&F=T First… this early-stage energy company made the critical leap from “potential developer” to “actual oil producer!” Then… Cougar Oil and Gas expanded its oil production and its oil-rich acreage in Alberta (where an astounding 1.7 trillion barrels of oil is economically recoverable).

Now… serious investors are taking notice and Cougar Oil and Gas`s share price looks to spike within days.

Analysts have just announced that COUGF is hugely undervalued, and have set the target price at $7.25…that`s a serious gain You do NOT want to miss this one.

http://www.sgurunews.com/emailmarketer/link.phpM596&N48&L88&F=T “COUGF is an immediate opportunity that might be even more profitable than last year`s dramatic stock market moves.” “I know a great buying opportunity when I see one. I`m not talking about making 25%. . .30%. . . or 45% on your money, but more like 500% on your money, this could be a once or twice in a lifetime opportunity” P.S.

4,370% in 60 months Why not The management team running Cougar Oil and Gas took part in launching three of the most successful oil startups of all time: Pennaco Oil, Velvet Exploration, and Ultra Petroleum, which soared 4,370% in 60 months.

They can certainly do it again.

COUGF All the reasons why are in my just-published report, which is yours free today. Select here for free and instant access and discover my top 5 Reasons To Invest in COUGF Now:

5 Reasons You Need to Buy COUGF Today 1. Amex listing coming soon. Buy COUGF today before the stock moves from the OTC to Amex…They`ve just applied for the listing…

Watch the video here…

http://www.sgurunews.com/emailmarketer/link.phpM596&N48&L88&F=T 2. Cash flow & Production. Projected oil production to be 15,000 barrels or more by 2013. Cougar Oil and Gas already has cash flow, unlike most other junior exploration companies. The cash is flowing in because Cougar is already pumping oil out of the ground…400% more than last year alone…The land position could produce enough drill locations to produce up to 120,000 barrels of oil per day!!! Watch the video here…

http://www.sgurunews.com/emailmarketer/link.phpM596&N48&L88&F=T 3. Peak Oil. A barrel of oil sells for about $83 today. By next year, according to the Peak Oil Theory, that same barrel will cost $100. Do the math, how much will a barrel be worth in 2013 $300, $400, $500+ Watch the video here…

http://www.sgurunews.com/emailmarketer/link.phpM596&N48&L88&F=T 4. Location. Location. Location. Cougar has 450,000 acres between all its projects. This is the largest land position in Alberta and the second largest land position in all of Canada. With current Alberta land sales, the value of land that Cougar has is worth at least $5 per share, without the oil!!! Watch the video here…

http://www.sgurunews.com/emailmarketer/link.phpM596&N48&L88&F=T 5. Management.Critical to the success of not just the company but also its investors, smart investors insist on proven track records.

The team running Cougar Oil and Gas are all-stars. Watch the video here…

http://www.sgurunews.com/emailmarketer/link.phpM596&N48&L88&F=T Did I mention…

* Cougar Oil and Gas (COUGF) has money in the bank, they`re already producing, and they`re expected to finalize an agreement in the coming weeks giving them access to 350,000 more acres in the Alberta Oil Sands…

* Over the next 24 months, I see the stock flying into the $15…

$17… $19 neighbourhood, turning a modest $5,000 investment into $67,849.

* And why you need to own shares today! http://www.sgurunews.com/emailmarketer/link.phpM596&N48&L88&F=T My name is John Person.

I am a 32 year seasoned investor and the author of several best selling books on investing. I got my start on the Floor of the Chicago Mercantile Exchange back in 1979. I`ve worked my way through the industry as an independent Trader, Broker, and owner of a brokerage firm.

I`ve written books, teach trading courses, and I`ve been widely quoted on CBS Market Watch, Reuters, Dow Jones Newswire, and CNBC.

The personal contacts I`ve developed around the world and in the financial industry have been instrumental in helping me gain an edge on information pertaining to the markets.

I know stocks.

I urge you, call your broker about COUGF [ WATCH THE REPORT HERE ] http://www.sgurunews.com/emailmarketer/link.phpM596&N48&L88&F=T View full disclaimer here http://www.sgurunews.com/emailmarketer/link.phpM596&N48&L86&F=T ..

Paid Advertising – Pentony Enterprises LLC “PE” The report and content of this presentation is a paid advertisement. It was paid for by a non-controlling third party for dissemination of this copy. We have taken no shares. To avoid all potential conflicts of interest, we never sell shares into the open market during an active market awareness or investor relations program. This means that as we release new information about a particular client company either on our site or otherwise authored by us, you can be confident we are not selling shares at the same time. We hold no shares and will not be receiving further compensation in shares or that is share related during this period. Total compensation from the third party for sending this and other advertising copy associated with COUGF totals no more than twenty four thousand dollars. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. As advertising, PE was hired for the distribution of the attached content. PE did not author or endorse the content, and as a rule never does when hired for advertising. Paid Advertising – Pentony Enterprises LLC 1601 Berwick Drive McKinney, Texas 75070 (469) 252-3031.

..To stop receiving these emails:http://www.sgurunews.com/emailmarketer/

COUGF